Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis-A Systematic Review and...

Area of Science:

• Pulmonology
• Pharmacology
• Critical Care Medicine

Background:

• Hemoptysis, or coughing up blood, requires effective management to reduce patient morbidity.
• Traditional treatments for hemoptysis include embolization and medications.
• Tranexamic acid (TXA), an antifibrinolytic, is being investigated for hemoptysis via inhalation for targeted delivery and reduced systemic effects.

Approach:

• A systematic literature search was conducted across major databases (PubMed Central, EMBASE, SCOPUS, ProQuest).
• Included studies were randomized controlled trials (RCTs) and observational studies on inhalational TXA for nonmassive hemoptysis.
• Meta-analysis techniques were used to pool effect estimates.

Key Points:

• Analysis of 5 studies (3 RCTs, 2 observational) involving 351 patients indicated nebulized TXA was 3.85 times more likely to achieve hemoptysis cessation.
• Patients receiving nebulized TXA required 43% fewer pulmonary interventional procedures.
• A trend towards reduced post-therapy bleeding was observed, though not statistically conclusive.

Conclusions:

• Nebulized tranexamic acid presents a potential therapeutic option for nonmassive hemoptysis.
• The current evidence suggests benefits in halting bleeding and reducing invasive procedures.
• Higher quality RCTs with larger sample sizes are necessary to solidify these findings and guide clinical practice.